TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02258204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924911
Drug: GSK1322322
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four different formulations of 1000mg of GSK1322322
Study: NCT00924911
Drug: GSK1322322
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 1000mg
Study: NCT00454090
Drug: AZD8330
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03293654
Drug: MB02
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study: NCT03293654
Drug: US licenced Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Study: NCT00587379
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pill per day
Study: NCT04494984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study: NCT00819416
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin for the first 7 days of care in the ICU
Study: NCT00819416
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline for the first 7 days of care in the ICU
Study: NCT03726177
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT04882007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03960502
Drug: [13C315N3]AG-881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV microdose of approximately 100 μg.
Study: NCT03711162
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690, film-coated tablets for oral use.
Study: NCT03711162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, film-coated tablets for oral use.
Study: NCT02431754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03427359
Drug: cisplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
Study: NCT01275066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
Study: NCT02871128
Drug: supplement
Normalized name: fat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Study: NCT01581463
Drug: Liothyronine, Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 100-microgram (2 X 50 microgram) dose.
Study: NCT03569371
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054707 administered once daily orally with water without regard to food for 8 weeks.
Study: NCT00291122
Drug: celecoxib 400 mg BID
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01344369
Drug: Norethindrone/Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/0.035 mg Chewable Tablets
Study: NCT01344369
Drug: FEMCON® Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/0.035 mg Chewable Tablets
Study: NCT03383328
Drug: NSAID + prednisolone, preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Study: NCT03383328
Drug: NSAID + prednisolone, postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Study: NCT03383328
Drug: NSAID, preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Study: NCT03383328
Drug: NSAID, postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Study: NCT03383328
Drug: Drop-less surgery
Normalized name: lesser galangal root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
Study: NCT04573036
Drug: HRS4800 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration
Study: NCT04573036
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration
Study: NCT01641367
Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
Study: NCT01641367
Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
Study: NCT01782781
Drug: ropivacaine, ketorelac and epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group
Study: NCT01782781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group
Study: NCT01827657
Drug: GSK2336805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
Study: NCT03237728
Drug: 0.06mg/kg,KB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06mg/kg,Q8h,Day1-Day7
Study: NCT03237728
Drug: 0.12mg/kg,KB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12mg/kg,Q8h,Day1-Day7
Study: NCT03237728
Drug: 0.24mg/,KB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24mg/kg,Q8h,Day1-Day7
Study: NCT03237728
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos,Q8h,Day1-Day7
Study: NCT02079688
Drug: SB011, 2 % (Water/Oil/Water) emulsion of hgd40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Study: NCT02079688
Drug: Multiple W/O/W formulation, active ingredient-free vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Study: NCT02686294
Drug: HL151
Normalized name: Hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug : HL151. 1T, once a day oral administration, for 4 days
Study: NCT02586493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 1 inhalation once-daily until visit 2.
Study: NCT02615457
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granule was given orally, 20 g tid for 5 years.
Study: NCT00964431
Drug: Celecoxib 400 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules 2 x 200 mg Single-Dose
Study: NCT00964431
Drug: Indomethacin Test (lower dose)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mg single dose
Study: NCT00964431
Drug: Indomethacin Test (upper dose)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-mg single dose
Study: NCT01442363
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ointment
Study: NCT00688480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule, orally for 9 months
Study: NCT02984384
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
Study: NCT02984384
Drug: Low Molecular Weight Heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
Study: NCT01299831
Drug: Olbetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours.
Study: NCT02759120
Drug: Antimicrobial therapy: Co-trimoxazole or Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
Study: NCT00969787
Drug: DWP05195
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, oral administration, single and multiple administrations
Study: NCT00808743
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib: 400mg twice daily, orally, 6 months
Study: NCT00808743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
Study: NCT01434524
Drug: LIVACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIVACT contains 13.0 g of free amino acids
Study: NCT02711423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
Study: NCT01839552
Drug: Fentanyl Citrate Nasal Spray (FCNS)
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02493738
Drug: Lozanoc 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozanoc 50mg single dose under fed and fasted condition
Study: NCT01718756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
Study: NCT01718756
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery
Study: NCT01718756
Drug: Scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia.
Study: NCT00524160
Drug: Fentanyl transdermal patch
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01965808
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01828034
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01400867
Drug: Cephalexin or Clindamycin or Linezolid
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
Study: NCT03060434
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
Study: NCT00262548
Drug: Rosuvastatin; improvement of lipid profile
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00786695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical looking Placebo, same regimen, for 14 days
Study: NCT01103934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once daily
Study: NCT02735070
Drug: Resfenol
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Study: NCT02735070
Drug: Coristina d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Study: NCT00337103
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
Study: NCT00404352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
Study: NCT02712944
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone
Study: NCT00984854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
Study: NCT02667483
Drug: DS-5141b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5141b, Subcutaneous injection
Study: NCT01520363
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
Study: NCT00486265
Drug: AZD4877
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion administered on days 1, 2 and 3
Study: NCT00852709
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
Study: NCT00132418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03690388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
Study: NCT00389116
Drug: gastrograffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ingestion
Study: NCT01094548
Drug: Single low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
Study: NCT01094548
Drug: Multiple low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
Study: NCT04648865
Drug: LY3537031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04648865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT03088176
Drug: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
Normalized name: TALIMOGENE LAHERPAREP 100 MIL PFU/ML 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
Study: NCT02250196
Drug: PEG-Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study: NCT02250196
Drug: SPMC 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Study: NCT00144365
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04619706
Drug: FSD201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04619706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matched to FSD201 for oral administration.
Study: NCT04446065
Drug: Previfenon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
Study: NCT04446065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
Study: NCT03681457
Drug: LJN452
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A single dose
Study: NCT01073865
Drug: ZD9393 (Zoladex) 10.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
Study: NCT01073865
Drug: ZD9393 (Zoladex) 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
Study: NCT01667666
Drug: Nebulized hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
Study: NCT00641095
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets
Study: NCT01526889
Drug: LFG316
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFG316 administered intravitreally (IVT)
Study: NCT01526889
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy administered in accordance with its prescribing info.
Study: NCT02078583
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes